DalCor Pharmaceuticals Lands $150,000,000 Series B Financing Round

  • Feed Type
  • Date
    4/20/2016
  • Company Name
    DalCor Pharmaceuticals
  • Mailing Address
    400 S. El Camino Real San Mateo, CA 94402 USA
  • Company Description
    DalCor is focused on providing precision medicine through identification of genetically distinct patient populations that derive clinical benefits. By integrating clinical, biologic and genetic insights, DalCor intends to deliver superior outcomes in clinical medicine.
  • Website
    http://www.dalcorpharma.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $150,000,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    DalCor will use the proceeds to fund a Phase 3 clinical trial of dalcetrapib, a CETP inhibitor, in patients who have recently experienced Acute Coronary Syndrome (ACS).
  • M&A Terms
  • Venture Investor
    Sanderling Ventures
  • Venture Investor
    Investor
  • Venture Investor
    Fonds de solidarite FTQ
  • Venture Investor
    CTI Life Sciences Fund
  • Venture Investor
    CDC – Caisse des Depots
  • Venture Investor
    Undisclosed